Jump to ContentJump to Main Navigation
Show Summary Details
In This Section

European Journal of Nanomedicine

Editor-in-Chief: Hunziker, Patrick / Mollenhauer, Jan

Managing Editor: Löffler, Beat / Salieb-Beugelaar, Georgette

Editorial Board Member: Alexiou, Christoph / Balogh, Lajos / Barenholz, Yechezkel / Dawson, Kenneth / Fadeel, Bengt / Husseini, Ghaleb / Krol, Silke / Lee, Dong Soo / Lehr, Claus-Michael / Mangge, Harald / Müller, Bert / Peer, Dan / Scoles, Giacinto / Serruys, Patrick / Schwartz, Simo / Szebeni, Janos

4 Issues per year


CiteScore 2016: 1.06

SCImago Journal Rank (SJR) 2015: 0.355
Source Normalized Impact per Paper (SNIP) 2015: 0.436

Online
ISSN
1662-596X
See all formats and pricing
In This Section

Novel radioisotope-based nanomedical approaches

Birgitte Brinkmann Olsen
  • Corresponding author
  • PET and Cyclotron Unit, Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark
  • These authors contributed equally.
  • Email:
/ Helge Thisgaard
  • PET and Cyclotron Unit, Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark
  • Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
  • These authors contributed equally.
/ Stefan Vogel
  • Nucleic Acid Center and the Biomolecular Nanoscale Engineering Center, Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Denmark
/ Mads Thomassen
  • Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
  • Department of Clinical Genetics, Odense University Hospital, Odense, Denmark
/ Torben A. Kruse
  • Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
  • Department of Clinical Genetics, Odense University Hospital, Odense, Denmark
/ David Needham
  • Center for Single Particle Science and Engineering, Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Denmark
  • Department of Mechanical Engineering and Material Science, Pratt School of Engineering, Duke University, Durham, NC, USA
/ Jan Mollenhauer
  • Lundbeckfonden Center of Excellence NanoCAN and Molecular Oncology Group, Institute for Molecular Medicine, University of Southern Denmark, Odense, Denmark
/ Poul Flemming Høilund-Carlsen
  • PET and Cyclotron Unit, Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark
  • Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
Published Online: 2013-12-02 | DOI: https://doi.org/10.1515/ejnm-2013-0025

Abstract

Radioisotope therapy of cancer is on the rise applying mainly β-emitting radionuclides. However, due to exposure of healthy tissues, the maximum achievable radiation dose with these is limited. Auger-electron emitters (AEs) represent a promising alternative because of their mode of decay within a short nanometer range. The challenge is that their therapeutic efficacy relies on a close vicinity to DNA. To overcome this and to minimize toxicity, the construction of smart nanomedical devices is required, which ascertain tumor cell targeting with succeeding cellular uptake and nuclear translocation. In this review we describe the potential of AEs with focus on their delivery down to the DNA level and their cellular effects. Reported efforts comprise different tumor-targeting strategies, including the use of antibodies or peptides with nuclear localizing sequences. Recently, attention has shifted to various nanoparticle formats for overcoming delivery problems. To this end, these approaches have mostly been tested in cell lines in vitro applying AEs more suited for imaging than therapy. This defines a demand for nanomedical formulations with documented in vivo activity, using AEs selected for their therapeutic potential to come closer to real clinical settings.

Keywords: Auger-electron emitters; DNA damage; nuclear targeting; radionuclide therapy; tumor targeting

Introduction

α-, β- or Auger-electron emission from radionuclides can be used to treat cancer by irradiating and killing tumor cells in targeted radionuclide therapy. Currently approved radiopharmaceuticals include a group of agents that specifically accumulate in a given target tissue, e.g., 131I, which accumulates in thyroid tissue (1) or antibodies that target cell surface molecules found on tumor cells. The latter include, for example, Zevalin and Bexxar, which are radiolabeled antibodies against CD20 on B-cells in non-Hodgkin lymphoma labeled with 90Y and 131I, respectively (2).

The use of radionuclides for cancer therapy has been suggested already back in 1938 (3), and has been put into practice in benign and malignant thyroid disease in 1943 and 1946, respectively, applying the β-emitter 131I, which is still in use for this purpose (1, 4). Since iodine is part of the thyroid hormone it is absorbed from the digestive tract and transported by the blood to be extracted by and organically bound in the gland, thus reducing radiation to non-target organs. In theory, 131I appears to be an ideal clinical radioisotope, but in reality, things are more complicated and even if radioiodine therapy of thyroid diseases has been a tremendous clinical success (5–8), the approach needs optimization and is not directly applicable in other types of cancer.

Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors applies β-emitters 177Lu or 90Y for irradiation, an approach that has proved effective in tumors with a high concentration of somatostatin receptors (SSTRs) because the radioisotopes in this setting are mainly absorbed by the tumors or excreted by the kidneys (9, 10). Unfortunately, although helpful, this kind of therapy is not curative, probably because the risk of kidney and bone marrow damage limits the maximum achievable dose (9). Furthermore, β-emitters rely on cross-fire effects from surrounding labeled cells in order to increase the radiation dose to the tumor but this effect is insignificant for micro-metastases or single tumor cells. Thus, there is a risk that these tumor cells receive a too low radiation dose to be effectively killed.

Therefore, other isotopes with better radiation characteristics and with fewer side effects have been matter of intense searches. The potential of low-energy Auger electrons in cancer therapy has been suggested some decades ago, when their ability to induce complex and severe damage to DNA was discovered (11). However, due to their short-range emission, it has become clear that Auger electron emitter-based radiotherapy requires adequate tumor delivery, high nuclear accumulation and retention as well as that the radionuclides need to be in close proximity to DNA to have therapeutic value. This review will focus on recent developments in tumor-targeting, internalization and nuclear translocation/DNA binding that have been made with respect to the use of Auger-electron emitters (AEs) in the treatment of cancer.

AEs in targeted radionuclide therapy

Conventionally, isotopes emitting long-range β-particles are used for radionuclide therapy of cancer (12), but in recent years encouraging results have also been obtained with radionuclides emitting low-energy electrons, e.g., Auger- and conversion electrons (13–19).

Auger electrons (here used as the collective name for Auger, Coster-Kronig and super Coster-Kronig electrons) are low-energy orbital electrons emitted from the atomic shells of the decaying nuclide. They are created as a result of atomic de-excitation following the creation of an electron vacancy (hole) in an electron capture (EC) decay or internal conversion (IC) process. In the de-excitation process, the vacancy is rapidly filled with an electron from a higher energy state and the remaining energy is then either emitted as a characteristic X-ray photon or an Auger electron. In the latter case, an additional vacancy is created (Figure 1). The de-excitation process is then repeated so the vacancies are moved towards the outermost shell and thus, a cascade of Auger electrons is created. On average, 5–30 electrons with energies ranging from a few eV to some keV, are emitted from a nuclide undergoing an EC decay or an IC process (12).

Figure 1

Illustration of the Auger-process. When the initial vacancy is created from the EC-decay or the IC-process, electronic transitions lead to the emission of characteristic X-rays and/or Auger-electrons.

The high biological toxicity and the considerable therapeutic potential of these low-energy electron-emitters are mainly associated with the very high ionization density created in biological tissue (high-LET-like effect) from their decay (12, 15). This is a consequence of the emission of this electron cascade in each radioactive decay, with all electrons having low energies and thus, resulting short ranges in biological tissue.

Consequently, the decay leads to a highly localized energy deposition in the vicinity of the decay site (Figure 2), corresponding to an extremely high and local radiation dose. Further, as a consequence of the short range, it is conceptually possible to minimize the undesirable radiation dose to the normal tissue and resulting side effects, by ensuring that the radionuclides are not internalized into the healthy cells, which might be achieved by the use of appropriate targeting mechanisms and devices (14, 15, 20, 21). It has thus been proposed that it should be possible to administer a large amount of radioactivity of these isotopes to a patient to increase the therapeutic effect, while keeping the side effects in the critical organs at a minimum (22). The short-range radiation potentially makes this type of radionuclides particularly suited for therapy of small metastases and disseminated cancer cells, owing to the minimal irradiation the surrounding, normal tissue would be exposed to, in contrast to the application of conventional β-particle emitters, which currently are undergoing clinical trials (17, 21, 23).

Figure 2

The spatial ionization (*) patterns associated with α-, β- and Auger decays. In the vicinity of the Auger-decay site, a very high ionization density is created giving rise to the high-LET effects also observed with α-particles.

Due to the electron-ranges of AEs that typically are less than one cell diameter, it is important that the radionuclides are internalized into the cancer cells – and, preferably, into the cell nuclei in close vicinity to the DNA to maximally exploit this biological effect (12, 13, 15, 17, 18). If the decaying nuclides are located in the cell nucleus, close to the DNA, high-LET-like effects are observed (the so-called “Auger effect”). Effects resembling the effects observed with α-particles, resulting in a survival curve with no shoulder and Relative Biological Effectiveness (RBE) values of up to approximately 9 (24). On the other hand, if the decay takes place in the cytoplasm, at the cell surface or in the extracellular space, the effects resemble those observed with low-LET radiation e.g., X-rays or β-particles with a pronounced shoulder on the survival curve (20, 24–26).

The therapeutic effectiveness of AEs, once inside the nucleus, occurs mainly through extensive DNA damage that is difficult to repair because the most deleterious forms of DNA damage; clusters of DNA double strand breaks (DSBs) are caused. This was highlighted in recent experiments using 125I attached to a DNA intercalator, which revealed that the number of DNA DSBs decreases as the 125I atom is located farther away from the DNA. The scavenger dimethyl sulfoxide (DMSO) did not affect the DNA DSB yield when the distance between DNA and 125I was below 1,2 nm supporting a complete direct effect. However, above 1,2 nm, no DSBs were observed in the presence of DMSO supporting completely indirect effects (27).

Delivery to target cells – carriers for AEs

Currently, delivery of AEs in vivo faces a number of challenges, including the delivery vehicle, tumor markers to ensure selective targeting, and nuclear translocation and DNA targeting functionalities (Figure 3). Tumor targeting has focused on the use of antibodies (28, 29), peptides, which serve as ligands for cell surface receptors (14, 30), and nanoparticles (31).

Figure 3

Schematic drawing showing different methods for targeting the AEs to the tumor cell, the nucleus and the DNA.

Once binding occurs of (A) an antibody- or (B) a peptide-conjugate to their cognate cell surface receptors, the conjugate is internalized. However, only if the conjugate is modified by a nuclear localization sequence (NLS) are the AEs efficiently transported to the nucleus via the importin α/β complex, leading to nuclear accumulation of the AEs. (C) Nanocarriers, here exemplified by a liposome loaded with AEs conjugated to a DNA intercalator. The particles are targeted to the tumor cells via an antibody conjugated to nanocarrier surface. Once inside the cell, the AE-intercalator translocates to the nucleus and binds to DNA. When the AEs are in very close proximity to DNA, they can induce highly toxic DNA DSBs.

Increased nuclear targeting has generally been attempted to be optimized using a nuclear localization sequence (NLS), most often from the SV40 Large T-antigen. The NLS is recognized by the importin α/β heterodimer which shuttles the cargo across the nuclear pore complex (32). Though, no DNA binding occurs via this technique and hence, no high-LET-effects, the radiation dose to the DNA increases by increasing the amount of activity located in the nuclei of the targeted tumor cells. Nuclear targeting has also been analyzed using nucleosides, oligonucleotides, DNA intercalators, hormone receptor ligands, which associate with DNA or peptide ligands that target a cell surface receptor, which then in turn itself translocates to the nucleus (33).

Antibodies

Antibodies used for delivery of AEs to cancer cells include antibodies against cell surface proteins, particular in hematological malignancies such as CD74 (34–36) or CD33. When used in combination with 111In and a nuclear localization sequence the antibodies caused localization of 111In to the nucleus of drug-resistant AML (acute myeloid leukemia) cell lines and primary tumor cells and decreased clonogenic survival (18, 37).

Several groups have also focused on antibodies targeting the epidermal growth factor receptor (EGFR) or human epidermal growth factor receptor 2 (HER2), which are frequently overexpressed in cancer (38, 39). 111In-nimotuzumab and 111In-NLS-nimotuzumab were both internalized by EGFR overexpressing breast cancer cells. 111In-NLS-nimotuzumab quickly accumulated in the nucleus, induced more DNA damage and consequently was more effective in reducing clonogenic survival in vitro. However, in vivo the NLS-conjugate had a lower tumor uptake than the conjugate without NLS (40).

Similarly, the anti-HER2 antibody trastuzumab modified with NLS-peptides and conjugated to 111In was internalized in breast cancer cells, efficiently accumulated in the nucleus and was more cytotoxic compared to the radiolabeled antibody without NLS. In contrast to the results with nimotuzumab, there was an increased nuclear uptake of 111In-NLS-trastuzumab in HER2-positive tumor xenografts and the mice had a significantly longer survival time compared to mice treated with unlabeled antibody. Furthermore, the addition of NLS peptides did not alter the biodistribution of the immunoconjugate (19, 41).

As described above, the introduction of a nuclear localization sequence might affect the in vivo behavior. For example, when an unspecific antibody, labeled with 111In, was conjugated to the cell penetrating peptide tat (transactivator of transcription), which also harbors an NLS, it increased blood elimination and increased nuclear accumulation not only in breast cancer xenografts but also in liver and kidney cells (42). This emphasizes the complexity of changes introduced by additional functionalities and defines a demand for platform nanomedical approaches, which result in more predictable behavior.

Peptides

Several malignant tumors overexpress cell surface receptors, which can be targeted with radiolabeled receptor-specific peptides. Much attention has been paid to peptides that bind the somatostatin receptor which is, for example, overexpressed in neuroendocrine tumors (43).

Inclusion of an NLS at the N-terminal part of the somatostatin analogue peptide DOTATOC (DOTA-[Tyr3]-octreotide) labeled with 111In, increased cell retention and increased nuclear accumulation of the radioisotope, whereas placing the NLS at the C-terminal part of the peptide had no effect or even decreased internalization compared to unmodified 111In-DOTATOC (44). However, recent results from our group (unpublished) indicate that liver uptake is strongly increased in vivo in tumor-bearing mice by inclusion of the NLS at the N-terminal of 111In-DOTATOC compared to unmodified radioligand. More recently, an analogue of the DNA intercalator Hoechst was conjugated to the somatostatin analogue TATE ([Tyr3, Thr8]-octreotide) and labeled with 125I to form 125I-Hoechst-TATE. The conjugate was internalized through an SSTR2-receptor-mediated mechanism, but only a small fraction of the internalized radioactivity accumulated in the nucleus, albeit a higher fraction compared to a complex without Hoechst (125I-TATE). The labeled peptides both localized to human xenografts in mice, however, the addition of the Hoechst moiety resulted in a larger proportion of radioactivity localizing to the liver as compared to 125I-TATE alone, which predominantly was found in the kidneys (45).

Other surface receptors have also been used for targeting of peptide-ligands, including EGFR for breast cancer. Reilly et al. initially showed that EGF (epidermal growth factor) conjugated to 111In was internalized in breast cancer cells overexpressing EGFR. Approximately 15% of the internalized radioactivity accumulated in the nucleus within 24 h. This resulted in a decreased growth rate and decreased cell survival. In vivo, no morphological changes were seen in either kidney or liver, the two organs, in which most of the radioactivity was distributed (14).

Specific binding of the F3 peptide from human high mobility group protein 2 (HMGN2), labeled with 111In, to nucleolin on the surface of tumor cells led to internalization in breast cancer cells and translocation to the nucleus and nucleoli, causing DNA damage and reduced clonogenic survival in cells. Furthermore, in vivo the conjugate arrested tumor growth, though tumor uptake was modest and most of the radioactivity was found in the blood and the kidneys (46). The F3 peptide has also been radiolabeled with 125I, which also internalized in vitro, albeit no biological effects were evaluated (47).

99mTc conjugated to bombesin binds gastrin-releasing peptide receptor (GRP-r), which is overexpressed on the surface of several types of cancer cells (48). To increase internalization and nuclear delivery, a tat sequence was included. The conjugate was internalized into prostate- and breast cancer cell lines and translocated to the nucleus, causing a significant decrease in cellular proliferation in vitro (49).

Nanoparticles

Nanoparticles are thought to passively target tumors due to the enhanced permeability and retention effect (EPR), which may result from the disorganized tumor vasculature [reviewed in (50)]. Accordingly, passively targeting nanoparticles were historically the first ones to be tested. Recent strategies, however, focused on modifying the nanoparticle surface by attaching tumor-targeting units such as antibody-fragments, peptides or small molecules, which further enhance accumulation in the tumor through active targeting mechanisms via molecular interactions (51–61).

So far nanomedical approaches have generated a large number of drug delivery systems for radio-isotope imaging, including, for example, liposomes (62–65), iron oxide (66–68), polymers (69), dendrimers (70) and carbon nanotubes (71). Here we focus on recent studies using nanoparticles for delivery of AEs to tumor cells for therapeutic purposes, although so far most of them have the drawback of only being tested in vitro.

Liu et al. constructed 3-component nanoparticles consisting of a biotinylated anti-tumor antibody (Herceptin or trastuzumab for tumor cell targeting), a biotinylated penetrating peptide (tat for internalization and nuclear translocation) and a biotinylated 111In-labeled antisense oligonucleotide (for DNA binding) all held together by streptavidin. The 111In-labeled oligonucleotide accumulated in the nucleus of HER2 overexpressing cells and was cytotoxic for the cells (51, 52), which shows the validity of the approach, albeit in vivo studies remain to be performed.

A so-called modular nanotransporter could also enhance the nuclear accumulation and cytoxicity of 125I in EFGR-overexpressing cell lines. The modular nanotransporters are recombinant multifunctional polypeptides, which ensure receptor binding and internalization (EGF), endosomal escape (DTox; a translocation domain from diphtheria toxin) and nuclear translocation (NLS) (53).

Multifunctional block copolymer micelles (BCMs, nanoassemblies of amphilic copolymers) were labeled with 111In and conjugated with EGF. Uptake and nuclear accumulation was compared to 111In-EGF in breast cancer cell lines and although cellular uptake of the BCMs was lower than of 111In-EGF, a fraction of 111In-EGF-BCM accumulated in the nucleus and gave a six-fold inhibition of cell growth in vitro compared to non-treated cells (54). Sedlacek et al. described an approach, where 125I was covalently bound to a DNA-intercalating derivative of ellipticine and conjugated to a polymer with a pH-controlled release of the 125I-ellipticine in endosomes plus DNA targeting via the intercalator. In vitro experiments showed that this nanoparticle accumulated in the nucleus and was cytotoxic in a panel of cancer cell lines (55).

Recently, a two-step targeting method was described for transporting 125I into the nucleus of cells using PEG (polyethylene glycol)-stabilized liposomes, called nuclisomes. The liposomes were conjugated to EGF and were loaded with 125I-Comp1. Comp1 is an intercalating daunorubicin derivative, employed for DNA intercalation in this setting. The nuclisomes were taken up by human EGFR-overexpressing glioma cells and considerably delayed cell growth in vitro (56). In another study, the nuclisomes were conjugated with a targeting device for HER2 and these were specifically taken up by HER2-overexpressing cells in vitro and reduced cancer cell survival (57). Furthermore, when the nuclisomes targeted to HER2 were given to mice carrying human ovarian cancer xenografts, they accumulated in the tumors and there was a significant difference between treated and mock treated animals since more than 50% of the surviving mice were tumor-free. In addition, no macroscopic or microscopic radiotoxic side effects were observed in the mice (31, 57, 58) supporting the nuclisome approach in specific also in vivo and the feasibility of the AE-based radiotherapy in general.

Cellular responses to AEs

DNA double-strand breaks (DSBs) are highly deleterious and their formation is a major determinant of the cytotoxicity of radiation therapy as well as of several chemotherapeutic agents. An early event following the formation of DSBs is the phosphorylation of histone H2AX at serine 139 by the PI3K-like kinases [i.e., DNA-PK (DNA dependent protein kinase), ATM (ataxia telangiectasia mutated) and ATR (ATM and Rad3-related)], resulting in γH2AX (72). The formation of γH2AX foci is abundant, fast, and correlates with DSBs, making it a sensitive marker that can be used to analyze DSBs. Indeed, this is a widely used method when evaluating the therapeutic potential of AEs in vitro. The assay is often performed in addition to an assay that measures cellular survival/cell death since this is the ultimate endpoint response after radiation. Cells can die via different mechanisms following radiation-induced DNA damage, with the most important mode for solid tumor cells being mitotic death, i.e., the result of aberrant mitosis and a delayed type of cell death (73). Other modes of cell death following radiation include apoptosis and autophagy or the cells can enter senescence – a permanent cell cycle arrest. Below we summarize the biological effects and cellular responses caused by AEs in vitro and in vivo as well as some of the so far known determinants.

Chromatin structure influences radiosensitivity to external irradiation (74), but also to internal radiation since fewer DNA DSBs are induced in supercoiled DNA than in nicked or relaxed DNA by the AE 125I in vitro (75). 111In-EGF induced more DNA damage and stronger reduction of clonogenic survival, when the cells had been pretreated with inhibitors of histone deacetylases to relax DNA. Similarly, condensation of the chromatin resulted in fewer γH2Ax foci (76). Conjugation of 111In to NLS and an antibody, which preferentially recognizes leukemia stem cells, reduced the viability of AML cells. This was associated with DNA DSBs as visualized by γH2Ax foci (77). Conjugation of a fragment of vascular endothelial growth factor (VEGF) to 111In induced DNA DSBs and was cytotoxic in porcine aortic endothelial cells overexpressing the Flt1-receptor. This effect was increased by introducing a nuclear localization sequence (30). The internalizing anti-EGFR (cytoplasmic localization) and the non-internalizing anti-CEA (carcinoembryonic antigen, cell surface bound), both conjugated with 125I, induced mitotic death in human colon cancer cells (78).

Bystander effects

Part of the AE radiotoxicity has been shown in vitro and in vivo to be due to bystander effects, which occur when radio-damaged cells induce cell death in neighboring non-irradiated cells. However, bystander effects not only include cell death, but also DNA damage, genomic instability, transformation, invasion, proliferation and radio-adaptive responses (79). The mechanisms behind bystander effects remain to be completely established, but direct cellular communication through gap junctions and indirect mechanisms through the release of signaling molecules play important roles (79–81).

Bystander effects have mostly been described for external radiation; however several reports describe bystander effects induced by AE radionuclides both in cell culture and in animal models. Medium from human glioma or bladder carcinoma cells (donor cells), incubated with 123I-meta-iodobenzylguadinine (MIBG) increased cell killing in 35%–70% of recipient cells (cells not incubated with 123I-MIBG), depending on the cell line used. The effect however, was only seen at low activity concentrations, while at higher activities, the bystander effect became progressively weaker (82). This effect was supported by results using 123I-UdR (iodo-deoxyuridine), which is incorporated into the DNA during DNA synthesis, in a colon cancer cell line, which showed a dose-dependent decrease in the surviving fraction of bystander cells, but only at low concentrations. At higher concentrations the toxicity was relieved, suggesting that 123I may elicit a toxic or protective effect on neighboring cells at low and high dose, respectively (83). In contrast, Kishikawa et al. found that 123I induced stimulatory bystander effects in human colon cancer cells and increased survival both in vitro and in vivo, whereas 125I-UdR showed toxic bystander effects (84). Inhibitory bystander effects were also observed with 125I-UdR in vitro in chinese hamster V79 cells (85), in colon cancer cells (86) and in the breast cancer cell line MCF7 (84). However, in another breast cancer cell line (MDA-MB-231) no bystander effects were observed indicating that differences in the phenotypes of cells also could play a role in the induction of bystander effects (87). In vivo experiments using human colon carcinoma cells, labeled with a lethal dose of 125I-UdR prior to mixing with unlabeled cells and before injection into nude mice showed a significant inhibitory effect on tumor growth due to bystander effects in the non-labeled cells (88). Understanding and mastering of bystander effects via smart nanomedical delivery systems with modulatory functionalities could represent one of the future routes.

Therapeutic aspects

To fully take advantage of AEs in cancer therapy, i.e., to exploit the “Auger effect”, it is imperative that the radionuclide is targeted to tumor cells, internalized, and transported to the nucleus in very close proximity to DNA, to which the electrons are damaging and lethal. A possible approach to improve the efficacy of AE therapy could be to amplify the potency of the targeted radiation by combining with other anti-cancer treatments e.g., radio-sensitizers, chemotherapy, small-molecule inhibitors, external irradiation or even gene therapy. Ultimately, this may warrant more sophisticated nanomedical delivery systems with, for example, timed release of different components.

The general feasibility of the conception has been demonstrated by some recent studies. Trastuzumab-resistent cell lines could be killed by 111In and this effect was stronger when cells were radiosensitized by methotrexate, which further reduced clonogenic survival in breast cancer cells (28). But also other low-dose chemotherapeutics (paclitaxel and doxorubicin) sensitized breast cancer cells to 111In-NLS-Trastuzumab, which was ascribed to changes in cell cycle distribution and/or changes in DNA damage repair by the chemotherapeutic drugs (89).

Cornelissen et al. used the combination of external radiation and the 111In-anti-γH2Ax-tat conjugate in breast cancer cells and in xenografts. Cells were allowed to internalize the conjugate (via tat) and irradiated to allow the formation of γH2Ax, which is then targeted by the antibody bringing the AE into close proximity to the DNA. In vitro, there was an increase in γH2AX foci and a decrease in survival after external radiation combined with the radiolabeled conjugate. In vivo, the result was a decreased growth rate of the tumors compared to either treatment alone. Hence, the combination of external and internal therapy amplifies the DNA damage and increases the antitumor effect in vivo (46). This was further expanded, using a bi-specific conjugate, introducing EGF as part of the conjugate to allow tumor cell targeting, either in a cleavable or non-cleavable form, however only the cleavable form of the immune-conjugate accumulated in the nucleus after external irradiation and decreased clonogenic survival (90).

When EGFR activity was abolished by the small molecule inhibitor gefitinib, the nuclear accumulation of 111In-EGF was significantly higher than without gefitinib and this was accompanied by an increase in the number of γH2Ax foci and reduced clonogenic survival in breast cancer cells (91).

The AE molecule 125I-UdR was combined with gene therapy, by introducing the anti-tumor protein IFNγ into mouse hepatoma tumors in mice under the control of a radiation-sensitive promoter. This means that IFNγ is only expressed when the cells are irradiated, externally or internally. The tumors were injected with the IFNγ-DNA and 125I-UdR in combination or alone. The combination decreased the tumor volume and the mean survival of the mice injected with both was significantly longer than with 125I alone, whereas mice injected with IFNγ plasmid alone had the same survival as control mice (92).

Finally, when block copolymer micelles (BCMs) were conjugated with 111In, an NLS sequence and a HER2 specific antibody and loaded with the radiosensitizer methotrexate, the micelles were taken up by HER2 overexpressing cells in vitro. 111In accumulated in the nucleus and the concomitant low-dose methotrexate further reduced cell survival (93).

However, efficient delivery of therapeutic and imaging agents is hindered by macrophages which quickly detect and engulf nanoparticles. In the past, this has been circumvented by masking the nanoparticles with polyethylene glycol [reviewed in (94)]. A new promising approach has been the discovery of “self-peptides” i.e., a peptide sequence derived from cluster of differentiation 47 (CD47), which prevents phagocytosis by macrophages when attached to the nanoparticle surface (95). Additional self-peptides are likely to exist and could also be used to further avoid phagocytosis and thereby increase delivery of therapeutics and imaging agents to cancer cells.

Clinical use

111In-octreotide was already tested for treatment of neuroendocrine tumors in patients in the late 1990s, and high doses led to symptomatic relief. However, tumor regression was rare with the most common long-term side effects being to the bone marrow (96–98). Several reasons may be responsible for these somewhat disappointing results, one being the choice of radionuclide. For these studies, 111In was probably chosen for its availability, but it is a suboptimal therapeutic radionuclide providing a low so-called tumor-to–normal-tissue mean absorbed dose-ratio in comparison to much better suited AEs like 119Sb or 58mCo (99). The second reason is probably the lack of sufficient nuclear entry as this is a key precondition for a sufficient amount of DNA DSBs (72). Furthermore, for large, bulky tumors with heterogeneous uptake of the radiopharmaceutical, the lack of cross-fire into unlabeled cells from AEs may result in cells escaping the therapy. For such tumors a long-range β-emitter is better suited – or even better in combination with an AE in a “cocktail approach” to effectively kill the disseminated, circulating tumor cells and micro-metastases. This circumstance and a still limited but growing understanding of the biological effects of Auger processes may explain, why the significance of AEs has been largely ignored by the medical community despite their extreme localized radiotoxicity, which in theory makes them ideally suited for targeted DNA damage in single cells and micro-metastases, and thus for treating of disseminated cancer with very limited side effects. A steadily increasing amount of knowledge on the characteristic and biological behavior of AEs has been collected since the possible benefits of their damaging effect were addressed by Feinendegen in 1975 (11). Despite the many promising observations and peculiar nature of the Auger processes, which in principle make them ideally suited for “internal” targeted radiation therapy as opposed to external irradiation, the clinical application is still in its infancy.

Perspectives

The future of AEs in medical use will no doubt be concentrated on cancer, since the vision is to target and kill all cancer cells. Due to the very short range of the emitted electrons it is generally accepted that AEs do not exhibit their extreme radiotoxicity, i.e., the “Auger effect”, unless situated very close to or in the DNA and, thus, they have unique properties not matched by other radioisotopes or external irradiation.

While AEs have great therapeutic potential in cancer therapy, the requirement of targeting not only all tumor cells but also their DNA presents a major hurdle. However, great progress has been made in recent years, albeit that many of the most promising approaches have so far only been tested in early preclinical settings and, hence, there is still room for improvement of the different phases of AE therapy.

We thank Karina Lindbøg Madsen for help with the figures. The work was supported by The Lundbeck Foundation (Center of Excellence NanoCAN), The Region Syddanmarks Forskningspulje, and The SDU2020 Excellence Program.

References

  • 1.

    Becker DV, Sawin CT. Radioiodine and thyroid disease: the beginning. Sem Nucl Med 1996;17:155–64. [Crossref]

  • 2.

    Tomblyn M. Radioimmunotherapy for B-cell non-Hodgkin lymphomas. Cancer Control 2012;19:196–203.

  • 3.

    Hertz S, Roberts A, Evans RD. Radioactive iodine as an indicator in the study of thyroid physiology. Proc Soc Exp Biol Med 1938;38:510–3. [Crossref]

  • 4.

    Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid. J Am Med Assoc 1946;132: 838–47. [Crossref]

  • 5.

    Bonnema SJ, Hegedüs L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev 2012;33:20–80.

  • 6.

    Silberstein EB. Radioiodine: the classic theranostic agent. Semin Nucl Med 2012;42:164–70. [Crossref]

  • 7.

    Molinaro E, Pieruzzi L, Viola D. Radioiodine post-surgical remnant ablation in patients with differentiated thyroid cancer: news from the last 10 years. J Endocrinol Invest 2012;35:16–20.

  • 8.

    Schlumberger M. Target therapies for radioiodine refractory advanced thyroid tumors. J Endocrinol Invest 2012;35:40–4.

  • 9.

    Sandström M, Garske-Román U, Granberg D, Johansson S, Widström C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med 2013;54:33–41.

  • 10.

    Hörsch D, Ezziddin S, Haug A, Gratz KF, Dunkelmann S, Krause BJ, et al. Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registry. Recent Results Cancer Res 2013;194:457–65.

  • 11.

    Feinendegen LE. Biological damage from the Auger effect, possible benefits. Radiat Environ Biophys 1975;12:85–99. [Crossref]

  • 12.

    Kassis AI, Adelstein SJ. Radiobiologic principles in radionuclide therapy. J Nucl Med 2005;46:4S–12S.

  • 13.

    Janson ET, Westlin JE, Ohrvall U, Oberg K, Lukinius A. Nuclear localization of In-111 after intravenous injection of [In-111-DTPA-D-Phe(1)]-octreotide in patients with neuroendocrine tumors. J Nucl Med 2000;41:1514–8.

  • 14.

    Reilly RM, Kiarash R, Cameron RG, Porlier N, Sandhu J, Hill RP, et al. 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J Nucl Med 2000;41:429–38.

  • 15.

    Capello A, Krenning EP, Breeman WA, Bernard BF, de Jong M. Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide. J Nucl Med 2003;44:98–104.

  • 16.

    Behr TM, Behe M, Lohr M, Sgouros G, Angerstein C, Wehrmann E, et al. Therapeutic advantages of Auger electron- over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies. Eur J Nucl Med 2000;27:753–65. [Crossref]

  • 17.

    O’Donnell RT. Nuclear localizing sequences: An innovative way to improve targeted radiotherapy. J Nucl Med 2006;47:738–9.

  • 18.

    Chen P, Wang J, Hope K, Jin LQ, Dick J, Camron R, et al. Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 la-beled with In-111 in human myeloid leukemia cells. J Nucl Med 2006;47:827–36.

  • 19.

    Costantini DL, Chan C, Cai Z, Vallis KA, Reilly RM. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med 2007;48:1357–68.

  • 20.

    Hofer KG. Biophysical aspects of Auger processes. Acta Oncol 2000;39:651–7. [Crossref]

  • 21.

    Buchegger F, Perillo-Adamer F, Dupertuis YM, Delaloye AB. Auger radiation targeted into DNA: a therapy perspective. Eur J Nucl Med Mol Imaging 2006;33:1352–63. [Crossref]

  • 22.

    Ochakovskaya R, Osorio L, Goldenberg DM, Mattes MJ. Therapy of disseminated B-cell lymphoma xenografts in severe combined immunodeficient mice with an anti-CD74 antibody conjugated with (111)indium, (67)gallium, or (90)yttrium. Clin Cancer Res 2001;7:1505–10.

  • 23.

    Murray D, McEwan AJ. Radiobiology of systemic radiation therapy. Cancer Biother Radiopharm 2007;22:1–23. [Crossref]

  • 24.

    Humm JL, Howell RW, Rao DV. Dosimetry of Auger-electron-emitting radionuclides: report no. 3 of AAPM Nuclear Medicine Task Group No. 6. Med Phys 1994;21:1901–15.

  • 25.

    Adelstein SJ, Kassis AI, Bodei L, Mariani G. Radiotoxicity of iodine-125 and other Auger-electron-emitting radionuclides: Background to therapy. Cancer Biother Radiopharm 2003;18:301–16.

  • 26.

    Boswell CA, Brechbiel MW. Auger electrons: Lethal, low energy, and coming soon to a tumor cell nucleus near you. J Nucl Med 2005;46:1946–7.

  • 27.

    Balagurumoorthy P, Xu X, Wang K, Adelstein SJ, Kassis AI. Effect of distance between decaying (125)I and DNA on Auger-electron induced double-strand break yield. Int J Radiat Biol 2012;88:998–1008.

  • 28.

    Costantini DL, Bateman K, McLarty K, Vallis KA, Reilly RM. Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate. J Nucl Med 2008;49:1498–505.

  • 29.

    Michel RB, Castillo ME, Andrews PM, Mattes MJ. In vitro toxicity of A-431 carcinoma cells with antibodies to epidermal growth factor receptor and epithelial glycoprotein-1 conjugated to radionuclides emitting low-energy electrons. Clin Cancer Res 2004;10:5957–66.

  • 30.

    Chan C, Cai Z, Su R, Reilly RM. 111In- or 99mTc-labeled recombinant VEGF bioconjugates: in vitro evaluation of their cytotoxicity on porcine aortic endothelial cells overexpressing Flt-1 receptors. Nucl Med Biol 2010;37:105–15. [Crossref]

  • 31.

    Gedda L, Fondell A, Lundqvist H, Park JW, Edwards K. Experimental radionuclide therapy of HER2-expressing xenografts using two-step targeting nuclisome particles. J Nucl Med 2012;53:480–7. [Crossref]

  • 32.

    Görlich D, Kostka S, Kraft R, Dingwall C, Laskey RA, Hartmann E, et al. Two different subunits of importin cooperate to recognize nuclear localization signals and bind them to the nuclear envelope. Curr Biol 1995;5:383–92. [Crossref]

  • 33.

    Cornelissen B, Vallis KA. Targeting the nucleus: an overview of Auger-electron radionuclide therapy. Curr Drug Discov Technol 2010;7:263–79. [Crossref]

  • 34.

    Griffiths GL, Govindan SV, Sgouros G, Ong GL, Goldenberg DM, Mattes MJ. Cytotoxicity with Auger electron-emitting radionuclides delivered by antibodies. Int J Cancer 1999;81:985–92. [Crossref]

  • 35.

    Govindan SV, Goldenberg DM, Elsamra SE, Griffiths GL, Ong GL, Brechbiel MW, et al. Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters. J Nucl Med 2000;41:2089–97.

  • 36.

    Michel RB, Brechbiel MW, Mattes MJ. A comparison of 4 radionuclides conjugated to antibodies for single-cell kill. J Nucl Med 2003;44:632–40.

  • 37.

    Kersemans V, Cornelissen B, Minden MD, Brandwein J, Reilly RM. Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences. J Nucl Med 2008;49:1546–54.

  • 38.

    Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002;29:3–9. [Crossref]

  • 39.

    Maguire HC Jr, Greene MI. The neu (c-erbB-2) oncogene. Semin Oncol 1989;16:148–55.

  • 40.

    Fasih A, Fonge H, Cai Z, Leyton JV, Tikhomirov I, Done SJ, et al. 111In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer. Breast Cancer Res Treat 2012;135:189–200. [Crossref]

  • 41.

    Costantini DL, McLarty K, Lee H, Done SJ, Vallis KA, Reilly RM. Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts. J Nucl Med 2010;51:1084–91.

  • 42.

    Cornelissen B, McLarty K, Kersemans V, Scollard DA, Reilly RM. Properties of [(111)In]-labeled HIV-1 tat peptide radioimmunoconjugates in tumor-bearing mice following intravenous or intratumoral injection. Nucl Med Biol 2008;35:101–10.

  • 43.

    Papotti M, Bongiovanni M, Volante M, Allìa E, Landolfi S, Helboe L, et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 2002;440:461–75. [Crossref]

  • 44.

    Ginj M, Hinni K, Tschumi S, Schulz S, Maecke HR. Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters. J Nucl Med 2005;46:2097–103.

  • 45.

    Lobachevsky P, Smith J, Denoyer D, Skene C, White J, Flynn BL, et al. Tumour targeting of Auger emitters using DNA ligands conjugated to octreotate. Int J Radiat Biol 2012;88:1009–18. [Crossref]

  • 46.

    Cornelissen B, Darbar S, Kersemans V, Allen D, Falzone N, Barbeau J, et al. Amplification of DNA damage by a γH2AX-targeted radiopharmaceutical. Nucl Med Biol 2012;39:1142–51. [Crossref]

  • 47.

    Bhojani MS, Ranga R, Luker GD, Rehemtulla A, Ross BD, Van Dort ME. Synthesis and investigation of a radioiodinated F3 peptide analog as a SPECT tumor imaging radioligand. PLoS One 2011;6:e22418.

  • 48.

    Hohla F, Schally AV. Targeting gastrin releasing peptide receptors: New options for the therapy and diagnosis of cancer. Cell Cycle 2010;9:1738–41. [Crossref]

  • 49.

    Santos-Cuevas CL, Ferro-Flores G, Rojas-Calderón EL, García-Becerra R, Ordaz-Rosado D, Arteaga de Murphy C, et al. 99mTc-N2S2-Tat (49–57)-bombesin internalized in nuclei of prostate and breast cancer cells: kinetics, dosimetry and effect on cellular proliferation. Nucl Med Commun 2011;32:303–13. [Crossref]

  • 50.

    Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Control Release 2012;164:138–44. [Crossref]

  • 51.

    Liu X, Wang Y, Nakamura K, Kawauchi S, Akalin A, Cheng D, et al. Auger radiation-induced, antisense-mediated cytotoxicity of tumor cells using a 3-component streptavidin-delivery nanoparticle with 111In. J Nucl Med 2009;50:582–90.

  • 52.

    Liu Y, Cheng D, Liu X, Liu G, Dou S, Xiao N, et al. Comparing the intracellular fate of components within a noncovalent streptavidin nanoparticle with covalent conjugation. Nucl Med Biol 2012;39:101–7. [Crossref]

  • 53.

    Slastnikova TA, Koumarianou E, Rosenkranz AA, Vaidyanathan G, Lupanova TN, Sobolev AS, et al. Modular nanotransporters: a versatile approach for enhancing nuclear delivery and cytotoxicity of Auger electron-emitting 125I. MI Res 2012;2:59.

  • 54.

    Fonge H, Lee H, Reilly RM, Allen C. Multifunctional block copolymer micelles for the delivery of 111In to EGFR-positive breast cancer cells for targeted Auger electron radiotherapy. Mol Pharm 2010;7:177–86.

  • 55.

    Sedlacek O, Hruby M, Studenovsky M, Kucka J, Vetvicka D, Kovar L, et al. Ellipticine-aimed polymer-conjugated auger electron emitter: multistage organelle targeting approach. Bioconjug Chem 2011;22:1194–201. [Crossref]

  • 56.

    Fondell A, Edwards K, Ickenstein LM, Sjöberg S, Carlsson J, Gedda L. Nuclisome: a novel concept for radionuclide therapy using targeting liposomes. Eur J Nucl Med Mol Imaging 2010;37:114–23. [Crossref]

  • 57.

    Fondell A, Edwards K, Unga J, Kullberg E, Park JW, Gedda L. In vitro evaluation and biodistribution of HER2-targeted liposomes loaded with an (125)I-labelled DNA-intercalator. J Drug Target 2011;19:846–55.

  • 58.

    Gedda L, Edwards K. Nuclisome – targeting the tumor cell nucleus. Tumour Biol 2012;33:661–7. [Crossref]

  • 59.

    Mollenhauer J, Knoop A, Bak M, Lænkholm AV, Thomassen M, Kruse TA, et al. Breast cancer stem cells: a moving target for cancer nanomedicine. Eur J Nanomed 2012;4:59–72.

  • 60.

    Sawant RR, Patel NR, Torchilin VP. Therapeutic delivery using cell-penetrating peptides. Eur J Nanomed 2013;5: 141–58.

  • 61.

    Chen WC, Zhang AX, Li SD. Limitations and niches of the targeting approach for nanoparticle drug delivery. Eur J Nanomed 2012;4;89–93.

  • 62.

    Sofou S. Surface-active liposomes for targeted cancer therapy. Nanomedicine (Lond) 2007;2:711–24. [Crossref]

  • 63.

    Ogihara I, Kojima S, Jay M. Differential uptake of gallium-67-labeled liposomes between tumors and inflammatory lesions in rats. J Nucl Med 1986;27:1300–7.

  • 64.

    Bao A, Goins B, Klipper R, Negrete G, Phillips WT. 186Re-liposome labeling using 186Re-SNS/S complexes: in vitro stability, imaging, and biodistribution in rats. J Nucl Med 2003;44:1992–9.

  • 65.

    Phillips WT, Goins BA, Bao A. Radioactive liposomes. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009;1: 69–83. [Crossref]

  • 66.

    Jarrett BR, Gustafsson B, Kukis DL, Louie AY. Synthesis of 64Cu-labeled magnetic nanoparticles for multimodal imaging. Bioconjug Chem 2008;19:1496–504. [Crossref]

  • 67.

    Lee HY, Li Z, Chen K, Hsu AR, Xu C, Xie J, et al. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med 2008;49:1371–9. [Crossref]

  • 68.

    Devaraj NK, Keliher EJ, Thurber GM, Nahrendorf M, Weissleder R. 18F labeled nanoparticles for in vivo PET-CT imaging. Bioconjug Chem 2009;20:397–401. [Crossref]

  • 69.

    Line BR, Mitra A, Nan A, Ghandehari H. Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates. J Nucl Med 2005;46:1552–60.

  • 70.

    Almutairi A, Rossin R, Shokeen M, Hagooly A, Ananth A, Capoccia B, et al. Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis. Proc Natl Acad Sci USA 2009;106:685–90. [Crossref]

  • 71.

    McDevitt MR, Chattopadhyay D, Jaggi JS, Finn RD, Zanzonico PB, Villa C, et al. PET imaging of soluble yttrium-86-labeled carbon nanotubes in mice. PLoS One 2007;2:e907. [Crossref]

  • 72.

    Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, et al. GammaH2AX and cancer. Nat Rev Cancer 2008;8:957–67.

  • 73.

    Eriksson D, Stigbrand T. Radiation-induced cell death mechanisms. Tumour Biol 2010;31:363–72. [Crossref]

  • 74.

    Belyaev IY. Radiation-induced DNA repair foci: spatio-temporal aspects of formation, application for assessment of radiosensitivity and biological dosimetry. Mutat Res 2010;704:132–41. [Crossref]

  • 75.

    Kassis AI. Molecular and cellular radiobiological effects of Auger emitting radionuclides. Radiat Prot Dosimetry 2011;143:241–7. [Crossref]

  • 76.

    Terry SY, Vallis KA. Relationship between chromatin structure and sensitivity to molecularly targeted auger electron radiation therapy. Int J Radiat Oncol Biol Phys 2012;83:1298–305. [Crossref]

  • 77.

    Leyton JV, Hu M, Gao C, Turner PV, Dick JE, Minden M, et al. Auger electron radioimmunotherapeutic agent specific for the CD123+/CD131- phenotype of the leukemia stem cell population. J Nucl Med 2011;52:1465–73.

  • 78.

    Paillas S, Boudousq V, Piron B, Kersual N, Bardiès M, Chouin N, et al. Apoptosis and p53 are not involved in the anti-tumor efficacy of 125I-labeled monoclonal antibodies targeting the cell membrane. Nucl Med Biol 2013;40:471–80. [Crossref]

  • 79.

    Mothersill C, Seymour C. Medium from irradiated human epithelial cells but not human fibroblasts reduces the clonogenic survival of unirradiated cells. Int J Radiat Biol 1997;71:421–7.

  • 80.

    Azzam EI, de Toledo SM, Gooding T, Little JB. Intercellular communication is involved in the bystander regulation of gene expression in human cells exposed to very low fluences of alpha particles. Radiat Res 1998;150:497–504. [Crossref]

  • 81.

    Kassis AI. Cancer therapy with Auger electrons: are we almost there? J Nucl Med 2003;44:1479–81.

  • 82.

    Boyd M, Ross SC, Dorrens J, Fullerton NE, Tan KW, Zalutsky MR, et al. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and Auger electron-emitting radionuclides. J Nucl Med 2006;47:1007–15.

  • 83.

    Boyd M, Sorensen A, McCluskey AG, Mairs RJ. Radiation quality-dependent bystander effects elicited by targeted radionuclides. J Pharm Pharmacol 2008;60:951–8. [Crossref]

  • 84.

    Kishikawa H, Wang K, Adelstein SJ, Kassis AI. Inhibitory and stimulatory bystander effects are differentially induced by Iodine-125 and Iodine-123. Radiat Res 2006;165:688–94.

  • 85.

    Howell RW, Bishayee A. Bystander effects caused by nonuniform distributions of DNA-incorporated (125)I. Micron 2002;33: 127–32.

  • 86.

    Mamlouk O, Balagurumoorthy P, Wang K, Adelstein SJ, Kassis AI. Bystander effect in tumor cells produced by Iodine-125 labeled human lymphocytes. Int J Radiat Biol 2012;88:1019–27.

  • 87.

    Akudugu JM, Azzam EI, Howell RW. Induction of lethal bystander effects in human breast cancer cell cultures by DNA-incorporated Iodine-125 depends on phenotype. Int J Radiat Biol 2012;88:1028–38.

  • 88.

    Xue LY, Butler NJ, Makrigiorgos GM, Adelstein SJ, Kassis AI. Bystander effect produced by radiolabeled tumor cells in vivo. Proc Natl Acad Sci USA 2002;99:13765–70. [Crossref]

  • 89.

    Costantini DL, Villani DF, Vallis KA, Reilly RM. Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab. J Nucl Med 2010;51:477–83.

  • 90.

    Cornelissen B, Waller A, Able S, Vallis KA. Molecular Radiotherapy using Cleavable Radioimmunoconjugates that Target EGFR and γH2AX. Mol Cancer Ther 2013;12:2472–82. [Crossref]

  • 91.

    Bailey KE, Costantini DL, Cai Z, Scollard DA, Chen Z, Reilly RM, et al. Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor. J Nucl Med 2007;48:1562–70.

  • 92.

    Yang W, Zhao JG, Li XY, Gong SL, Cao JP. Anti-tumor effect of 125I-UdR in combination with Egr-1 promoter-based IFNγ gene therapy in vivo. Radiat Environ Biophys 2010;49:705–14. [Crossref]

  • 93.

    Hoang B, Reilly RM, Allen C. Block copolymer micelles target Auger electron radiotherapy to the nucleus of HER2-positive breast cancer cells. Biomacromolecules 2012;13:455–65. [Crossref]

  • 94.

    Amoozgar Z, Yeo Y. Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2012;4:219–33. [Crossref]

  • 95.

    Rodriguez PL, Harada T, Christian DA, Pantano DA, Tsai RK, Discher DE. Minimal “Self” peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 2013;339:971–5. [Crossref]

  • 96.

    Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 2002;32:110–22. [Crossref]

  • 97.

    Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002;32:123–32. [Crossref]

  • 98.

    Buscombe JR, Caplin ME, Hilson AJ. Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med 2003;44:1–6.

  • 99.

    Bernhardt P, Forssell-Aronsson E, Jacobsson L, Skarnemark G. Low-energy electron emitters for targeted radiotherapy of small tumours. Acta Oncol 2001;40:602–8.

About the article

Birgitte Brinkmann Olsen

Birgitte Brinkmann Olsen studied biomedicine from 1996–2003 and obtained her PhD in biochemistry and molecular cell biology in 2006 from the University of Southern Denmark. From 2006 to 2011 she was a postdoctoral fellow at the University of Southern Denmark and since 2012 she has been employed at the PET and Cyclotron Center, Department of Nuclear Medicine at Odense University Hospital. Her research area includes cellular response to DNA damage, pre-clinical testing of new PET tracers and targeted radioisotope therapy of cancer.

Helge Thisgaard

Helge Thisgaard studied biophysics from 1998 to 2004 at the Niels Bohr Institute, University of Copenhagen, Denmark. In 2008 he received his PhD degree from the University of Copenhagen, Denmark. The PhD study, which was performed at Risoe National Laboratory, Denmark, was about production and biological evaluation of novel Auger-electron-emitting radionuclides for cancer therapy. In 2008–2009 he worked as a radiation therapy physicist at Odense University Hospital, Denmark. Since 2009 he has been a nuclear medicine physicist at the Department of Nuclear Medicine, Odense University Hospital and in 2010 he was appointed as assistant professor at the Clinical Institute, University of Southern Denmark. His research area is production and biological evaluation of novel Auger-electron-emitting radioisotopes for targeted radionuclide therapy of cancer.

Stefan Vogel

Stefan Vogel studied chemistry from 1991 to 1997 at the University of Leipzig, Germany. He worked as a researcher on antibiotic drugs at Aventis AG, Paris, France from 1997 to 1998 and received his Doctor of Natural Sciences in 2001 from the University of Leipzig. After a postdoctoral period in 2001–2002 with Prof. Jesper Wengel at the University of Southern Denmark (SDU) on nucleic acids, he was appointed as assistant professor in 2003 and continued independent research on chemically modified nucleic acids. In 2006 he became associate professor at SDU and has been affiliated with the Nucleic Acid Center (NAC) and more recently as co-PI with the Biomolecular Nanoscale Engineering Center (BioNEC).

Mads Thomassen

Mads Thomassen studied chemistry and biotechnology at Aarhus University 1991–1998. From 1999 until 2000 he performed functional analysis and RNA profiling of lymphocytes in epidemiological studies of occupational medicine at Aarhus University. In 2000–2001 he was scientific assistant at DNA Technology A/S, Aarhus where he developed molecular diagnostic systems for leukemia. In 2001–2010 he worked and performed a PhD. study at Department of Biochemistry, Pharmacology and Genetics at Odense University Hospital and University of Southern Denmark. From 2010 he became Molecular Biologist at Department of Clinical Genetics, Odense University Hospital and assistant professor at Clinical Institute, University of Southern Denmark. His research area is molecular genetic analysis, gene expression and genome profiling, using next generation sequencing, of breast, ovarian and hematological cancers. He is co-author on 46 scientific publications.

Torben A. Kruse

Torben A. Kruse studied biostructural chemistry, physics and mathematics at Aarhus University and got his masters degree in 1977 and his PhD in 1982. After a postdoctoral-period at NIH and Harvard Medical School he was, in 1983, appointed assistant professor at the Institute of Human Genetics, Aarhus University. In 1987 he became associate professor there and from 1995 to 1987 Head of the Department. Since 1998 he has been professor in medical molecular genetics at the Department of Clinical Genetics, Odense University Hospital. In 2000 he became the founding leader of the Human MicroArray Centre, OUH, and since 2008 scientific coordinator of the National Strategic Research Network, DBCG-TIBCAT.

David Needham

David Needham studied chemistry from 1971 to 1975 at Trent Polytechnic, Nottingham, UK, and received his PhD in Physical Chemistry in 1981 from the University of Nottingham. He continued his studies in lipid membrane biophysics as a post-doctoral scientist with Prof. Dennis Haydon FRS at the Physiological Laboratory in Cambridge, and then obtained a NATO scholarship to study with Prof. Evan Evans at the University of British Columbia, Canada. He has been on the Faculty at the Duke University since 1987, and is now full Professor in the School of Engineering. In the Fall of 2012 he was awarded a Hans Christian Andersen Visiting Professorship at University of Southern Denmark (SDU). He is currently the Grundforskningsfonden Niels Bohr Visiting Professor in the Department of Physics Chemistry and Pharmacy at SDU, and Director of the Center for Single Particle Science and Engineering.

Jan Mollenhauer

Jan Mollenhauer studied biology from 1989 to 1994 at the University of Cologne, Germany, and received his PhD in 1998 from the University of Heidelberg, Germany. In 2003 he received his habilitation in Molecular Medicine from the University Heidelberg, which was mentored by the Nobel laureate in Medicine or Physiology 2008, Prof. Harald zur Hausen. Until 2008 he worked as group leader in the Division of Molecular Genome Analyses (Head: Prof. Annemarie Poustka) at the German Cancer Research Center, Heidelberg. In 2008 he joined the University of Southern Denmark, Odense, as Professor for Molecular Oncology. Since 2010, he is director of the Lundbeckfonden Center of Excellence NanoCAN (Nanomedicine Research Center for Cancer Stem Cell Targeting Therapeutics) and since 2011 leads the EU-Interreg4A-funded German-Danish High-Technology Platform for Innovative Disease Research (HiT-ID).

Poul Flemming Høilund-Carlsen

Poul F. Høilund-Carlsen studied philosophy, economy and languages in Copenhagen 1962–1965 and medicine in Aarhus 1966–1970 and Copenhagen 1970–1972. The postgraduate training was performed in Copenhagen with education as specialist in Clinical Physiology (1982) and in Clinical Physiology and Nuclear Medicine (1983). He received the Doctor of Medical Sciences 1988, Copenhagen University and was appointed Head of the new Department of Clinical Physiology and Nuclear Medicine in Holbæk, Denmark (1990–1993). Since 1993 Poul F. Høilund-Carlsen has worked as Professor of Clininal Physiology, University of Southern Denmark, Odense, and held a position as Head of the Department of Nuclear Medicine, Odense University Hospital 1994–2007. Since 2007 he is Head of Research. Main research fields comprise: Nuclear cardiology, PET and molecular imaging, targeted radioisotope therapy of cancer.


Corresponding author: Birgitte Brinkmann Olsen, PET and Cyclotron Unit, Department of Nuclear Medicine, Odense University Hospital, Sdr. Boulevard 29, 5000 Odense C, Denmark, E-mail:


Received: 2013-10-14

Accepted: 2013-11-13

Published Online: 2013-12-02

Published in Print: 2013-12-01



Citation Information: European Journal of Nanomedicine, ISSN (Online) 1662-596X, ISSN (Print) 1662-5986, DOI: https://doi.org/10.1515/ejnm-2013-0025. Export Citation

Comments (0)

Please log in or register to comment.
Log in